Meglumine antimoniate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Meglumine antimoniate
Meglumine antimoniate major component 3D.png
Clinical data
SynonymsMeglumine antimonate
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.004.645 Edit this at Wikidata
Chemical and physical data
Molar massVariable
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]

Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] The wholesale cost in the developing world is about 4.32 USD per vial as of 2014.[4] It is available in Southern Europe and Latin America but not the United States.[5][6]

Society and culture[edit]

It is manufactured by Aventis[7] and sold as Glucantime in France, and Glucantim in Italy.

See also[edit]


  1. ^ a b c d e f g WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 183. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
  2. ^ Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
  3. ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
  4. ^ "Meglumine Antimonate". International Drug Price Indicator Guide. Retrieved 8 December 2016.
  5. ^ Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 143773572X. Archived from the original on 2016-12-20.
  6. ^ Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
  7. ^ Aventis press release Archived 2014-05-22 at the Wayback Machine, 15 April 2005. (in German)